<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02277548</url>
  </required_header>
  <id_info>
    <org_study_id>UPCC 43313</org_study_id>
    <nct_id>NCT02277548</nct_id>
  </id_info>
  <brief_title>A Pilot Study at a Single-Institution of Pregabalin in the Management of Mucositis Pain in Patients Undergoing Chemoradiation Therapy to the Head and Neck.</brief_title>
  <official_title>A Pilot Study at a Single-Institution of Pregabalin in the Management of Mucositis Pain in Patients Undergoing Chemoradiation Therapy to the Head and Neck.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abramson Cancer Center of the University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abramson Cancer Center of the University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the efficacy of pregabalin in the management of mucositis pain in patients
      receiving radiotherapy to the head and neck. Eligible study subjects will be enrolled among
      those being treated for oropharyngeal cancer with definitive chemotherapy and radiation
      therapy (photons) to the head and neck in the Department of Radiation Oncology at the
      University of Pennsylvania.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2014</start_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Oropharyngeal Cancer</condition>
  <condition>Squamous Cell Carcinoma to the Head and Neck</condition>
  <arm_group>
    <arm_group_label>Lyrica at 300 mg per day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lyrica 300 mg</intervention_name>
    <description>Lyrica 300 mg per day</description>
    <arm_group_label>Lyrica at 300 mg per day</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients being treated for oropharyngeal cancer with undergoing concurrent
             chemotherapy and radiation therapy (photons) for a histological diagnosis of squamous
             cell carcinoma to the head and neck at the University of Pennsylvania

          -  Age at least 18 years old

          -  Treatment entails significant risk for symptomatic mucositis likely to require opioid
             analgesia, as per the discretion of treating physician/NP

          -  Subjects are capable of giving informed consent

        Exclusion Criteria:

          -  Patients anticipated to receive radiation therapy with Protons

          -  History of hypersensitivity to pregabalin or gabapentin

          -  History of seizure or currently taking anti-epileptic medication

          -  Creatinine clearance of less than 30 mL/min by Cockcroft-Gault estimate

          -  Has another painful condition requiring chronic use of opioid analgesic, gabapentin,
             or pregabalin

          -  History of serious mood disorder or attempted suicide as determined by patients
             history and physical and by using theDepression Screening

          -  Subjects with a score of greater than 10 or those answering #5 with scores greater
             than a &quot;0&quot; will be deemed ineligible to be enrolled on study

          -  History of angioedema

          -  New York Heart Association class III or IV heart failure

          -  Platelets of less than 150 mg/dL or history of thrombocytopenia

          -  The patient has any uncontrolled intercurrent illness including but not limited to
             psychiatric illness/social situations that would limit compliance or interfere with
             their ability to participate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Erin McMenamin, MSN, CRNP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Abramson Cancer Center of the University of Pennsylvania</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Erin McMenamin, MSN, CRNP</last_name>
    <phone>855-216-0098</phone>
    <email>PennCancerTrials@emergingmed.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Abramson Cancer Center of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erin McMenamin, MSN, CRNP</last_name>
      <phone>855-216-0098</phone>
      <email>PennCancerTrials@emergingmed.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 27, 2014</study_first_submitted>
  <study_first_submitted_qc>October 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 29, 2014</study_first_posted>
  <last_update_submitted>July 31, 2017</last_update_submitted>
  <last_update_submitted_qc>July 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>chemotherapy</keyword>
  <keyword>radiation therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Mucositis</mesh_term>
    <mesh_term>Oropharyngeal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pregabalin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

